ETOPOSIDE
Apatinib
The First Affiliated Hospital of Xiamen UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Apatinib cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib The First Affiliated Hospital of Xiamen University | Phase 3 | BB |
FLUOROURACILUM Huashan Hospital | Phase 3 | B |
Eloxatin Guohui Xu | Phase 3 | B |
Carboplatin The First Affiliated Hospital of Xiamen University | Phase 2 | B |
Inno-206 Guohui Xu | Phase 3 | B |
Adebrelimab The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II West China Hospital | Phase 1/2 | CC |
Capecitabine Nanchong Central Hospital | N/A | D |
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →